BioMedNewsBreaks

FridayDec 02, 2022 11:08 am

BioMedNewsBreaks — MetAlert Inc. (MLRT) Engages Veteran Firm as Financial Advisor to Assist with Growth Strategy, Corporate Development Initiatives

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, announced that Joseph Gunnar & Co. LLC will serve as the company’s financial advisor. According to the announcement, Joseph Gunnar will support the company as it communicates its growth strategy to the investment community; the firm will also provide advice on possible financing alternatives and acquisitions and will assist as MetAlert moves toward uplisting on a national exchange. Joseph Gunnar officials called MetAlert’s vision “compelling” and noted the company’s ability to leverage its extensive IP portfolio to bring valuable tech solutions to the…

Continue Reading

FridayDec 02, 2022 10:48 am

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Commences Trial Evaluating IGC-AD1 for the Treatment of Alzheimer’s-Related Symptoms

India Globalization Capital (NYSE American: IGC) announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” According to the announcement, the company has commenced the phase 2 study at two U.S. sites and plans to add between three to five additional sites in the United States, Canada and possibly South America. “We believe that IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s Disease as the first and only low-dose natural THC-based formulation candidate currently undergoing FDA trials,” said…

Continue Reading

ThursdayDec 01, 2022 1:34 pm

BioMedNewsBreaks — MetAlert Inc. (MLRT) ‘Groundbreaking’ Tech for Senior Health Care Market Spotlighted in Recent Article

MetAlert (OTC: MLRT), a pioneer in the field of wearable GPS human and asset tracking and remote patient monitoring, is featured in a recent Market Herald article for its proprietary technologies, including RoomMate(TM). The article, which is titled “One Company Is Set to Pioneer Technologies for the Senior Health Care Market,” reports on RoomMate, MetAlert’s groundbreaking 3D fall detection and monitoring device. The 3D infrared fall-detection, automated monitoring system provides “anonymized” supervision and monitoring service using infrared 3D tech. The article noted that more than 5,500 devices are in operation in Norway, Sweden, Denmark and Iceland, and the company is…

Continue Reading

ThursdayDec 01, 2022 11:58 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of a public offering. The offering is comprised of 1,889,764 shares of common stock (or prefunded warrants in lieu thereof) along with warrants to purchase up to 1,889,764 shares of common stock at a combined public offering price of $3.175 per share and associated warrant. The company noted that common warrants will be immediately exercisable at $3.03 per share and will expire five years following the initial exercise date. According to the announcement, the…

Continue Reading

ThursdayDec 01, 2022 10:57 am

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Present at RHK 2022 Disruptive Growth Conference

India Globalization Capital (NYSE American: IGC) has announced that its Chief Executive Officer Ram Mukunda will be presenting at the RHK Disruptive Growth Conference in New York City. Mukunda is slated to present beginning at 11:20 a.m. ET on Monday, Dec. 5, and will also be available for one-on-one meetings on Monday, Dec. 5 and Tuesday, Dec. 6. To view the full press release, visit https://ibn.fm/9Curx About India Globalization Capital Inc. India Globalization Capital develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s, Parkinson’s, chronic pain, and pet seizures. The company’s leading drug candidate, IGC-AD1, has…

Continue Reading

WednesdayNov 30, 2022 2:08 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q3 2022 Financial Results, Corporate Updates

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company that focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its third quarter, the period ending Sept. 30, 2022; the report also included key company updates. Highlights of the report included the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen; the three companies are working to develop a pipeline of innovative nanosized antibody (“NanoAb”) therapies. The company is also working to regain compliance with NASDAQ listing rules regarding minimum shareholders’ equity and minimum…

Continue Reading

WednesdayNov 30, 2022 11:00 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Changes to the Board of Directors

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced the appointments of Dr. Lakshmi P. Kotra and Joseph L. Romano to its board of directors, effective Nov. 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the board of directors. Dr. Kotra, an academic entrepreneur, has contributed to a number of important drug discovery and development projects, including metabolic disorders, neurodegenerative and immunological disorders, anti-HIV drugs, antibacterials, and antimalarials. He is the recipient of…

Continue Reading

TuesdayNov 29, 2022 3:47 pm

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference

BioRestorative Therapies (NASDAQ: BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that its CEO Lance Alstodt will be participating at the RHK Capital Disruptive Growth Conference. The event is slated to take place in New York City from Dec. 5-6, 2022, and feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies. Attendees will include seasoned institutional and accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers and select RHK clients. Interested parties should visit https://ibn.fm/XMA3b to learn more and submit a…

Continue Reading

TuesdayNov 29, 2022 1:35 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT), Sensio Group Partner to Distribute 3D Monitoring System – RoomMate(TM)

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today announced its entry into a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing RoomMate(TM). A 3D infrared monitoring system, RoomMate is a simple and effective solution for looking after patients without intruding on their personal space. The solution allows for a total “anonymized” supervision and monitoring service using infrared 3D technology with no wearables, cameras or devices needed. “We are very excited about this partnership and remarkable proven technology,” said MetAlert Business Development Director Andrew Duncan.…

Continue Reading

TuesdayNov 29, 2022 11:54 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “We are excited that the study results confirm the inhalation concept of our exclusively licensed NanoAb as a therapy for COVID-19 illness. Following these promising results, we intend to continue the study early next year by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive)…

Continue Reading